Arbutus Biopharma Corp. (ABUS)
4.265
-0.02
(-0.58%)
USD |
NASDAQ |
Oct 28, 12:26
Arbutus Biopharma Enterprise Value : 758.85M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 758.85M |
| October 26, 2026 | 741.06M |
| October 23, 2026 | 741.06M |
| October 22, 2026 | 743.04M |
| October 21, 2026 | 737.11M |
| October 20, 2026 | 766.76M |
| October 19, 2026 | 746.99M |
| October 16, 2026 | 745.02M |
| October 15, 2026 | 758.85M |
| October 14, 2026 | 739.09M |
| October 13, 2026 | 723.28M |
| October 12, 2026 | 731.18M |
| October 09, 2026 | 745.02M |
| October 08, 2026 | 737.11M |
| October 07, 2026 | 758.85M |
| October 06, 2026 | 796.40M |
| October 05, 2026 | 833.95M |
| October 02, 2026 | 790.47M |
| October 01, 2026 | 812.21M |
| September 30, 2026 | 855.69M |
| September 29, 2026 | 837.90M |
| September 28, 2026 | 871.50M |
| September 25, 2026 | 869.53M |
| September 24, 2026 | 875.45M |
| September 23, 2026 | 869.53M |
| Date | Value |
|---|---|
| September 22, 2026 | 901.15M |
| September 21, 2026 | 899.17M |
| September 18, 2026 | 901.15M |
| September 17, 2026 | 913.00M |
| September 16, 2026 | 909.05M |
| September 15, 2026 | 911.03M |
| September 14, 2026 | 924.86M |
| September 11, 2026 | 922.89M |
| September 10, 2026 | 922.89M |
| September 09, 2026 | 932.77M |
| September 08, 2026 | 934.74M |
| September 04, 2026 | 928.82M |
| September 03, 2026 | 922.89M |
| September 02, 2026 | 918.93M |
| September 01, 2026 | 916.96M |
| August 31, 2026 | 914.98M |
| August 28, 2026 | 913.00M |
| August 27, 2026 | 932.77M |
| August 26, 2026 | 936.72M |
| August 25, 2026 | 938.70M |
| August 24, 2026 | 938.70M |
| August 21, 2026 | 940.67M |
| August 20, 2026 | 853.71M |
| August 19, 2026 | 895.22M |
| August 18, 2026 | 867.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gossamer Bio, Inc. | 42.74M |
| Legend Biotech Corp. | 3.491B |
| ACADIA Pharmaceuticals, Inc. | 2.589B |
| Alnylam Pharmaceuticals, Inc. | 30.01B |
| Anika Therapeutics, Inc. | 272.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.143M |
| Revenue (Quarterly) | 1.014M |
| Total Expenses (Quarterly) | 6.157M |
| EPS Diluted (Quarterly) | -0.026 |
| Gross Profit Margin (Quarterly) | 98.92% |
| Profit Margin (Quarterly) | -507.2% |
| Earnings Yield | 18.37% |
| Operating Earnings Yield | 17.80% |
| Normalized Earnings Yield | 18.23 |